Omeros (NASDAQ:OMER) Downgraded to Sell Rating by StockNews.com

StockNews.com lowered shares of Omeros (NASDAQ:OMER) from a hold rating to a sell rating in a research report released on Wednesday morning.

A number of other analysts have also recently issued reports on the stock. Rodman & Renshaw assumed coverage on shares of Omeros in a research note on Thursday, November 14th. They issued a “buy” rating and a $9.00 target price for the company. D. Boral Capital reaffirmed a “buy” rating and issued a $36.00 price objective on shares of Omeros in a research note on Thursday, February 20th. Needham & Company LLC reiterated a “hold” rating on shares of Omeros in a report on Friday, January 17th. Cantor Fitzgerald restated a “neutral” rating on shares of Omeros in a report on Thursday, November 14th. Finally, RODMAN&RENSHAW upgraded Omeros to a “strong-buy” rating in a research note on Thursday, November 14th. One analyst has rated the stock with a sell rating, two have issued a hold rating, two have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $22.50.

Omeros Price Performance

OMER opened at $8.36 on Wednesday. The company has a market capitalization of $484.46 million, a PE ratio of -3.62 and a beta of 2.03. Omeros has a fifty-two week low of $2.61 and a fifty-two week high of $13.60. The business has a 50-day moving average of $9.18 and a 200-day moving average of $7.00.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the company. Two Sigma Investments LP grew its position in shares of Omeros by 8.8% in the fourth quarter. Two Sigma Investments LP now owns 162,991 shares of the biopharmaceutical company’s stock valued at $1,610,000 after purchasing an additional 13,201 shares during the last quarter. ProShare Advisors LLC boosted its stake in Omeros by 75.0% during the 4th quarter. ProShare Advisors LLC now owns 18,496 shares of the biopharmaceutical company’s stock valued at $183,000 after purchasing an additional 7,927 shares during the period. Nomura Holdings Inc. grew its holdings in Omeros by 136.2% in the 4th quarter. Nomura Holdings Inc. now owns 747,281 shares of the biopharmaceutical company’s stock valued at $7,383,000 after buying an additional 430,932 shares during the last quarter. Millennium Management LLC increased its position in Omeros by 46.2% in the 4th quarter. Millennium Management LLC now owns 85,671 shares of the biopharmaceutical company’s stock worth $846,000 after buying an additional 27,088 shares during the period. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in shares of Omeros by 3.6% during the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 31,831 shares of the biopharmaceutical company’s stock worth $314,000 after buying an additional 1,110 shares during the last quarter. Institutional investors own 48.79% of the company’s stock.

About Omeros

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.